Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Juluca | Dolutegravir rilpivirine | HIV infection | Reimburse with clinical criteria and/or conditions | Complete | ||
Jurnista | Hydromorphone hydrochloride | Pain, Chronic (moderate to severe) | Do not list | Complete | ||
Juxtapid | Lomitapide | Hypercholesterolemia, homozygous familial | Do not list | Complete | ||
Kadcyla | Trastuzumab Emtansine | Early Breast Cancer (EBC) | Reimburse | Complete | ||
Kadcyla | Trastuzumab emtansine | Advanced or Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Kalydeco | Ivacaftor | Cystic fibrosis, R117H CFTR gating mutation | List with criteria/condition | Complete | ||
Kalydeco | Ivacaftor | Cystic fibrosis, G551D mutation | List with criteria/condition | Complete | ||
Kalydeco | Ivacaftor | Cystic Fibrosis, CFTR gating mutations | List with criteria/condition | Complete | ||
Kanuma | sebelipase alfa | Lysosomal acid lipase deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
Kazano | Alogliptin plus metformin | Diabetes mellitus, type 2 | Do not list | Complete |